Search Results for "Constipation"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Constipation. Results 151 to 160 of 299 total matches.

Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia

   
The Medical Letter on Drugs and Therapeutics • Aug 18, 2014  (Issue 1449)
oxyhydroxide, while nausea and constipation were more common with sevelamer carbonate. As with other iron ...
Most patients with end-stage renal disease develop hyperphosphatemia, which can lead to secondary hyperparathyroidism, vascular calcification, and cardiovascular mortality. The FDA has approved sucroferric oxyhydroxide (Velphoro – Fresenius Medical Care), a chewable phosphate binder, for treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. It is the first iron-based phosphate binder to be approved for this indication.
Med Lett Drugs Ther. 2014 Aug 18;56(1449):76-7 |  Show IntroductionHide Introduction

Talimogene Laherparepvec (Imlygic) for Unresectable Melanoma

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
-like illness, injectionsite pain, nausea, vomiting, diarrhea, constipation, headache, myalgia ...
The FDA has approved talimogene laherparepvec (Imlygic – Amgen), a genetically modified herpes simplex virus, for intralesional treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma that has recurred following surgery. It is the first oncolytic virotherapy to become available in the US.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):8-9 |  Show IntroductionHide Introduction

Reduction of Cardiovascular Risk with Icosapent Ethyl (Vascepa)

   
The Medical Letter on Drugs and Therapeutics • Feb 10, 2020  (Issue 1591)
with placebo included musculoskeletal pain, peripheral edema, gout, and constipation. The incidence ...
Icosapent ethyl (Vascepa – Amarin), the ethyl ester of eicosapentaenoic acid (EPA), has been approved by the FDA for use as an adjunct to maximally tolerated statin therapy to reduce the risk of major adverse cardiovascular events in adults with hypertriglyceridemia (≥150 mg/dL) who have either established cardiovascular disease (CVD) or diabetes and ≥2 additional risk factors for CVD. It is the only omega-3 polyunsaturated fatty acid (PUFA) product to be approved in the US for this indication. Icosapent ethyl and two other omega-3 PUFA prescription products (Lovaza, Epanova),...
Med Lett Drugs Ther. 2020 Feb 10;62(1591):17-8 |  Show IntroductionHide Introduction

Plenity for Weight Management

   
The Medical Letter on Drugs and Therapeutics • May 17, 2021  (Issue 1624)
%), and constipation (5.4%). Most of these effects were mild, occurred within the first 3 months of treatment ...
Plenity (Gelesis), a nonsystemic oral superabsorbent hydrogel formulation of cellulose and citric acid is now available. It was cleared by the FDA in 2019 to aid in weight management together with diet and exercise in overweight and obese adults (BMI of 25-40 kg/m2). It is classified by the FDA as a device because the contents of the capsule are not absorbed systemically. Plenity is the first ingested, transient, space-occupying hydrogel to be marketed in the US and the only weight management treatment available by prescription for patients with a BMI of 25-30 kg/m2, regardless of...
Med Lett Drugs Ther. 2021 May 17;63(1624):77-8 |  Show IntroductionHide Introduction

A Donepezil Patch (Adlarity) for Alzheimer's Disease (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022  (Issue 1656)
, and pain, muscle spasms, insomnia, abdominal pain, constipation, diarrhea, dizziness, abnormal dreams ...
A once-weekly transdermal formulation of the acetylcholinesterase inhibitor donepezil (Adlarity – Corium) has been approved by the FDA for treatment of mild, moderate, and severe Alzheimer's disease (AD) dementia. Donepezil is the second acetylcholinesterase inhibitor to become available in a transdermal formulation; transdermal rivastigmine (Exelon Patch), which is applied once daily, has been available for years for the same indication. Donepezil is also available in oral formulations (Aricept, and generics) for treatment of AD dementia.
Med Lett Drugs Ther. 2022 Aug 8;64(1656):e128-9 |  Show IntroductionHide Introduction

Amivantamab (Rybrevant) for Non-Small Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
(frequency ≥20%) include paronychia, musculoskeletal pain, dyspnea, cough, nausea, stomatitis, constipation ...
Amivantamab-vmjw (Rybrevant – Janssen), an EGFR-MET bispecific antibody, has received accelerated approval from the FDA for IV treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults whose disease has progressed on or after platinum-based chemotherapy. It is the first bispecific antibody to become available in the US for this indication. Accelerated approval of the drug was based on the overall response rate and duration of response.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e184-5 |  Show IntroductionHide Introduction

Teclistamab-cqyv (Tecvayli) For Multiple Myeloma (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
, fatigue, upper respiratory tract infection, nausea, headache, diarrhea, constipation, and cough ...
Teclistamab-cqyv (Tecvayli – Janssen), a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, has been granted accelerated approval by the FDA for treatment of relapsed or refractory multiple myeloma in adults who received ≥4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody. Accelerated approval was based on response rate. Teclistamab is the first bispecific BCMA-directed CD3 T-cell engager to be approved in the US.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e196-7 |  Show IntroductionHide Introduction

Drugs for GERD and Peptic Ulcer Disease

   
The Medical Letter on Drugs and Therapeutics • Apr 04, 2022  (Issue 1647)
of GERD symptoms. Adverse Effects – Aluminum and calcium carbonate can cause constipation, and magnesium ...
Gastroesophageal reflux disease (GERD) is the most common GI condition encountered in the outpatient setting; it affects about 20% of people in the US.
Med Lett Drugs Ther. 2022 Apr 4;64(1647):49-56 |  Show IntroductionHide Introduction

Transdermal Fentanyl

   
The Medical Letter on Drugs and Therapeutics • Oct 16, 1992  (Issue 881)
fentanyl. Erythema and pruritus at the site of application, sweating, nausea, vomiting, constipation, dry ...
Fentanyl, a synthetic opioid previously available for parenteral use in anesthesia (Sublimaze), has now been marketed in a controlled-release transdermal formulation (Duragesic - Janssen) for use in patients with chronic pain severe enough to require opioid analgesia. It is not recommended for treatment of postoperative pain because of the drug's slow onset and prolonged duration of action.
Med Lett Drugs Ther. 1992 Oct 16;34(881):97-8 |  Show IntroductionHide Introduction

New Advertisement for An Old Antihistamine

   
The Medical Letter on Drugs and Therapeutics • Jan 22, 1993  (Issue 888)
, constipation, and abdominal pain. Clemastine is probably less sedating than diphenhydramine or a phenothiazine ...
Advertisements for clemastine (Tavist-1 - Sandoz), an ethanolamine oral antihistamine, have recently appeared on television and in major newspapers in the USA. Clemastine is an old drug (Medical Letter, 21:24, 1979) that has now become available without a prescription.
Med Lett Drugs Ther. 1993 Jan 22;35(888):9-10 |  Show IntroductionHide Introduction